why choose us

First received: March 17, 2023

Clinical Trial: A Phase 1 Study of ZL-1218 in Subjects With Advanced Solid Tumors

Study Status: Completed

Recruit Status: RECRUITING

Condition: Malignant Solid Tumor

Study Type: INTERVENTIONAL


Official Title: A Phase I, Open-label, Multicenter Study of ZL-1218 as a Single Agent and as Combination Therapy With Anti-PD-1 Antibody to Evaluate the Safety, Tolerability, and Pharmacokinetics in Subjects With Adv

Brief Summary: The purpose of this study is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antitumor activity of ZL-1218 as a single agent and as combination therapy in subjects with advanced solid tumor malignancies.

Read more